Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Isoguvacine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.92 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.92 |
| ▸ | GABRP | O00591 | 1/20 | 0.92 |
| ▸ | GABRD | O14764 | 1/20 | 0.92 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.92 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.92 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.92 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.92 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.92 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.92 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.92 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.92 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.92 |
| ▸ | GABRE | P78334 | 1/20 | 0.92 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.92 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.92 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.92 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.92 |
| ▸ | BLM | P54132 | 3/20 | 0.88 |
| ▸ | LMNA | P02545 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoguvacine SCHEMBL339700 | 0.96 | — | — | |
| Isoguvacine SCHEMBL6214170 | 0.94 | TSHR (0.96) | TSHRGABRR1GABRPGABRDGABRA1 | |
| Isoguvacine SCHEMBL7958625 | 0.94 | BLM (1.00) | TSHRGABRR1GABRPGABRDGABRA1 | |
| SCHEMBL9568927 | 0.80 | TSHR (0.72) | TSHRGABRR1GABRPGABRDGABRA1 | |
| SCHEMBL2032868 | 0.77 | — | — | |
| SCHEMBL29439268 | 0.77 | TSHR (0.67) | TSHRGABRR1GABRPGABRDGABRA1 | |
| SCHEMBL9497437 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL5249049 | 0.75 | BLM (0.68) | TSHRGABRR1GABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL14311854 | 0.75 | BLM (0.68) | TSHRGABRR1GABRPGABRDGABRA1 | |
| SCHEMBL29439332 | 0.73 | GABRR1 (0.62) | TSHRGABRR1GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872200-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| US-20210205248-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-08 | — | — | US | disclosed |
| US-10952980-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3753410-A2 | COMBINATIONS COMPRISING GABA AGONISTS IN TREATMENT OF HYPERGLYCEMIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-2621282-B1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | UNIV CALIFORNIA (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200030272-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-01-30 | — | — | US | disclosed |
| US-10434078-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180193295-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-07-12 | — | — | US | disclosed |
| US-9820955-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160081956-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-24 | — | — | US | disclosed |
| US-9089531-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130251671-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205248-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | GABRA4, GPR119, GABRG3 | TSHR 226/4885GABRR1 26/4885GABRP 19/4885 |
| US-20180193295-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | GABRA4, GPR119, GABRG3 | TSHR 226/4885GABRR1 26/4885GABRP 19/4885 |
| US-20160081956-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | GABRA4, GPR119, GABRG3 | TSHR 226/4885GABRR1 26/4885GABRP 19/4885 |
| US-10434078-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | GABRA4, GPR119, GABRG3 | TSHR 226/4885GABRR1 26/4885GABRP 19/4885 |
| US-11872200-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | GABRA4, GPR119, GABRG3 | TSHR 226/4885GABRR1 26/4885GABRP 19/4885 |
| US-20130251671-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | GABRA4, GPR119, GABRG3 | TSHR 226/4885GABRR1 26/4885GABRP 19/4885 |
| US-20200030272-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | GABRA4, GPR119, GABRG3 | TSHR 226/4885GABRR1 26/4885GABRP 19/4885 |
| US-10952980-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | GABRA4, GPR119, GABRG3 | TSHR 226/4885GABRR1 26/4885GABRP 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.